Taltz® Ixekizumab IXE
Humanized monoclonal IgG4 antibody, binds and blocks IL-17A
Medium to severe plaque psoriasis, approved from 18 years of age (PASI>10/BSA>10/DLQI>10, according to Swiss S1 guidelines). Available as syringe or PEN
Treatment of adult patients with severe psoriasis (Def. in USZ and Swiss S1 Guideline): PASI > 10 or BSA > 10 and/or DLQI > 10) in which UVB and PUVA or one of the following three systemic therapies (Ciclosporin, Methotrexate, Acitretin) have not shown therapeutic success. In Iximab, additional failure of another TNF blocker approved for psoriasis
Pre-filled syringe, pen
Blood count, liver enzymes, creatinine, U status, pregnancy test in urine, CRP/ ESR. Screening for HBV, HCV, HIV and tuberculosis including Rx thorax.
Blood count, CRP, transaminases, creatinine, possibly β-HCG
Every three months
Every three months
160 mg week 0, 80 mg week 2, 4, 6, 8, 10 and 12, since - after 80 mg every 4 weeks or (only in CH) at < 100 kg body weight from week 2 every 4 weeks 80 mg
77.5 - 84.2 % after 12 weeks 80 mg Taltz given every 4 weeks. 87.3 - 89.7 % after 12 weeks 80 mg Taltz at administration every 2 weeks.
59.7 - 65.3 % after 12 weeks 80 mg Taltz given every 4 weeks. 68.1 - 70.9 % after 12 weeks 80 mg taltz given every 2 weeks.
87 - 95 % achieve PASI 75 again after 24 weeks of re-treatment
PASI, (use PrecisePASI for greater accuracy once PASI < 10), DLQI after 12 and 24 weeks
Proven in 1.7 % of cases
Absolute contraindications: Active tuberculosis or acute, severe infections, live vaccinations, active chronic hepatitis B, pregnancy and breastfeeding. Relative contraindications: Crohn's disease (close monitoring). Malignant diseases (except BCC and lymphoproliferative diseases).
Candida infections (0.4 %), local reactions at the injection site, upper respiratory tract infections, tinea infection, nausea, diarrhoea, increased liver enzymes, oropharyngeal pain
Dose of medication interacting with CYP450 3A4, 1A2, or 2C9 should be re-evaluated.